Efficacy and safety of low-dose rituximab in the treatment of idiopathic membranous nephropathy
10.3760/cma.j.cn114015-20240403-00222
- VernacularTitle:低剂量利妥昔单抗治疗特发性膜性肾病的有效性和安全性
- Author:
Yao SONG
1
;
Hongge YANG
1
;
Aiping WEN
1
Author Information
1. 首都医科大学附属北京友谊医院药剂科，北京 100050
- Publication Type:Journal Article
- Keywords:
Glomerulonephritis, membranous;
Rituximab;
Dose-response relationship, drug;
Validation studies;
Safety;
Membranous nephropathy
- From:
Adverse Drug Reactions Journal
2024;26(10):615-619
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and safety of low-dose rituximab in the treatment of idiopathic membranous nephropathy (IMN).Methods:The medical record data of IMN patients treated with low-dose rituximab (375 mg/m 2 by IV infusion, administration once, and then decided whether to add drugs according to the patient′s situation) were searched from the electronic medical record system of Beijing Friendship Hospital, Capital Medical University from January 1, 2020 to June 30, 2023. The patients′ gender, age, 24-hour urinary protein quantitation, plasma albumin, serum creatinine, and the number of CD19 + B cells in peripheral blood before and 1, 3, and 6 months after rituximab application were collected. The efficacy (complete remission, partial remission, and no remission) and the occurrence of adverse reactions were retrospectively analyzed. Results:A total of 32 patients were enrolled in the study, including 24 males and 8 females, with mean age of (59±14) years. The 24-hour urinary protein of patients at 1, 3, and 6 months after the application of rituximab showed a decreasing trend, but the difference was not statistically significant ( P>0.05); after medication, plasma albumin showed an upward trend when compared with that before medication [(23.85±5.65)g/L], with values of (28.06±5.91), (30.56±6.87), and (32.47±7.69) g/L, respectively, and the differences were statistically significant ( P<0.05); the serum creatinine levels were within the reference range before and after medication, and the difference was not statistically significant ( P>0.05); the number of CD19 + B cells in peripheral blood significantly decreased after medication, and the difference was statistically significant ( P<0.05). The effective rate at 6 months after treatment was 65.62% (21/32), including complete remission rate of 9.38% (3/32), partial remission rate of 56.25% (18/32), and no remission rate of 34.38% (11/32). Eight patients experienced mild adverse reactions, all of which were improved after symptomatic treatments. Conclusion:Low-dose rituximab has good efficacy and safety in the treatment of IMN.
